Marek & Salek Extending the specificity of differential-reinforcement-of-low rate 72-s (DRL 72-s) behavior for screening antidepressant-like effects of glutamatergic clinically validated anxiolytic or antidepressant drugs in rats. J Pharmacol Exp Ther. Supplemental Fig. 1.



Supplemental Fig 1. Ketamine time course for 7.5 mg dose compared to vehicle on DRL 72-s behavior. The "7.5 ketamine" label reflects the 7.5 mg ketamine data displayed in Fig 5 of the manuscript. The D1, D2 and D7 data refer to reinforcers and total responses during the 60 min behavioral session 1, 2, and 7 days following the ketamine dose with the session conducted 1 h following drug administration. The same symbols are used for the vehicle and ketamine (day of administration) from Fig. 5 of the manuscript. The data 1,2, and 7 days following the 7.5 mg ketamine injection are displayed by green circles, green inverted triangles and green circles with a black surrounding line.

Marek & Salek Extending the specificity of differential-reinforcement-of-low rate 72-s (DRL 72-s) behavior for screening antidepressant-like effects of glutamatergic clinically validated anxiolytic or antidepressant drugs in rats. J Pharmacol Exp Ther. Supplemental Fig. 2.



Supplemental Fig 2. Ketamine time course for 15 mg dose compared to vehicle on DRL 72-s behavior. The "15 ketamine" label reflects the 15 mg ketamine data displayed in Fig 5 of the manuscript. The D1 and D7 data refer to reinforcers and total responses during the 60 min behavioral session 1 and 7 days following the ketamine dose with the session conducted 1 h following drug administration. The same symbols are used for the vehicle and ketamine (day of administration) from Fig. 5 of the manuscript. The data 1 and 7 days following the 15 mg ketamine injection are displayed by red diamonds and red circles with a black surrounding line.

Marek & Salek Extending the specificity of differential-reinforcement-of-low rate 72-s (DRL 72-s) behavior for screening antidepressant-like effects of glutamatergic clinically validated anxiolytic or antidepressant drugs in rats. J Pharmacol Exp Ther

Supplemental Table 1. Effects of LY354740, mGluR2 PAMs, mGlu2/3 receptor antagonists, and ketamine on Major Depressive Disorder (MDD) clinical trials, preclinical antidepressant screens, Generalized Anxiety Disorders (GAD) clinical trials, and preclinical anxiolytic drug screens.

	LY354740 (mGlu2/3 agonist)	mGlu2 receptor PAMs	mGlu2/3 receptor antagonists	Ketamine or Esketamine
MDD clinical trials	*not tested*	Negative[1]	Negative[2]	POSITIVE[3-8]
DRL 72-s behavior	Negative[9]	Positive[10,11]	Negative[12]	Positive[9,13,14]
Forced swim test	Negative[15,16,21]	Positive[10]	Positive[12,18,20-21]	Positive[20, 22-24,37]
Tail suspension test	Negative[15]	*not tested*	Positive[17,20,25]	Positive[20]
Olfactory bulbectomy	*not tested*	*not tested*	Positive[25]	Positive[26]
GAD clinical trials	POSITIVE[27,28]	*not tested*	*not tested*	*not tested*
Elevated plus maze	Positive[29-31,43]	Positive[32]	Negative[17,12]	Pos/neg[33-39]
Stress-induced hyperthermia	Positive[40,41]	Positive[41,10,47,50]	Pos/neg[12,42]	*not tested*
Lactate-induced panic	Positive[43]	Positive[44]	*not tested*	*not tested*
Fear potentiated startle	Positive[30,48]	Positive[49,50]	Pos/Neg[46,49]	Pos/neg[51-54]

1 (Kent et al., 2016)
2 (NCT01457677)
3 (Berman et al., 2000)
4 (Caddy et al., 2015)
5 (Daly et al., 2019)
6 (Fedgchin et al., 2019)
7 (Niciu et al., 2014)
8 (Papova et al., 2019)
9 (Marek & Salek, 2020, present manuscript)
10 (Fell et al., 2011)
11 (Nikiforuk, 2010)
12 (Bespalov et al., 2008; Hillhouse and Porter, 2014)
13 (Hillhouse and Porter, 2014)
14 (Hillhouse et al., 2014)
15 (Klodzinska et al., 1999)
16 (Witkin et al., 2017)
17 (Chaki et al., 2004)
18 (Witkin and Eiler, 2006)
19
20 (Witkin et al., 2016)
21 (Karasawa et al., 2005)
22 (Garcia et al., 2008)

(Autry et al., 2011)
(Salat et al., 2015)
(Palucha-Poniewiera et al., 2010)
(Holubova et al., 2016)
(Dunayevich et al., 2008)
(Michelson et al., 2005)
(Monn et al., 1997)
(Helton et al., 1998)
(Ferris et al., 2001)
(Galici et al., 2006)
(Silvestre et al., 1997)
(Loss et al., 2012)
(Kilic et al., 2014)
(Zhang et al., 2015)
(Engin et al., 2009)
(Hayase et al., 2006)
(Fraga et al., 2018)
(Spooren et al., 2002)
(Rorick-Kehn et al., 2006)
(Iijima et al., 2007)
(Shekhar and Keim, 2000)
(Johnson et al., 2013)
(Linden et al., 2004)
(Yoshimizu et al., 2006)
(Wieronska et al., 2012)
(Tizzano et al., 2002)
(Johnson et al., 2003)
(Johnson et al., 2005)
(Clifton et al., 2018)
(McGowan et al., 2017)
(Radford et al., 2018)
(Pietersen et al., 2006)